Advertisement

First view of the TESEO registry: From snapshots come photo albums

      The increased risk of thrombosis associated with cancer has been known since Trousseau's observations in the 19th century. Roughly 15 to 20 years ago, studies found that patients with cancer and thrombosis had a higher likelihood of recurrent thrombosis despite the use of anticoagulation, and an increased risk of bleeding with anticoagulation, than patients without cancer [
      • Prandoni P.
      • Lensing A.W.
      • Piccioli A.
      • et al.
      Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
      ]. At that time, cancer treatments were limited to combinations of surgery and radiation, and conventional chemotherapy with regimens comprised of chemical agents that impaired cell replication in an indiscriminate manner. Anticoagulation options were also limited, either to low molecular weight heparin (LMWH) given by injection only, or to warfarin, an oral medication but difficult to manage due to drug-drug and drug-food interactions, especially in the setting of conventional chemotherapy. Trials of warfarin vs LMWH revealed that LMWH had better efficacy at preventing recurrent venous thrombosis, although bleeding rates were similar with both, as demonstrated in the largest such randomized controlled trial (RCT), the CLOT trial [
      • Lee A.Y.
      • Levine M.N.
      • Baker R.I.
      • Bowden C.
      • Kakkar A.K.
      • Prins M.
      • Rickles F.R.
      • Julian J.A.
      • Haley S.
      • Kovacs M.J.
      • Gent M.
      Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators.Lee AY, et al.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Prandoni P.
        • Lensing A.W.
        • Piccioli A.
        • et al.
        Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
        Blood. 2002; 100: 3484-3488
        • Lee A.Y.
        • Levine M.N.
        • Baker R.I.
        • Bowden C.
        • Kakkar A.K.
        • Prins M.
        • Rickles F.R.
        • Julian J.A.
        • Haley S.
        • Kovacs M.J.
        • Gent M.
        Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators.Lee AY, et al.
        N Engl J Med. 2003; 349 (Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer): 146-153https://doi.org/10.1056/NEJMoa025313
        • Zugazagoitia J.
        • Biosca M.
        • Oliveira J.
        • Olmedo M.E.
        • Dómine M.
        • Nadal E.
        • et al.
        Incidence, predictors and prognostic significance of thromboembolic disease inpatients with advanced ALK-rearranged non-small cell lung cancer.
        Eur Respir J. 2018; 511702431
        • Al-Samkari H.
        • Leiva O.
        • Dagogo-Jack I.
        • Shaw A.
        • Lennerz J.
        • Iafrate A.J.
        • Bendapudi P.K.
        • Connors J.M.
        Impact of ALK rearrangement on venous and arterial thrombotic risk in non-small cell lung cancer.
        J Thorac Oncol. 2020; (May 10:S1556-0864(20)30380-4)
        • Raskob G.E.
        • van Es N.
        • Verhamme P.
        • Carrier M.
        • Di Nisio M.
        • Garcia D.
        • Grosso M.A.
        • Kakkar A.K.
        • Kovacs M.J.
        • Mercuri M.F.
        • Meyer G.
        • Segers A.
        • Shi M.
        • Wang T.F.
        • Yeo E.
        • Zhang G.
        • Zwicker J.I.
        • Weitz J.I.
        • Büller H.R.
        • Raskob G.E.
        • et al.
        • Hokusai VTE Cancer Investigators
        Edoxaban for the treatment of cancer-associated venous thromboembolism.
        N Engl J Med. 2018; 378: 615-624
        • Young A.M.
        • Marshall A.
        • Thirlwall J.
        • Chapman O.
        • Lokare A.
        • Hill C.
        • Hale D.
        • Dunn J.A.
        • Lyman G.H.
        • Hutchinson C.
        • MacCallum P.
        • Kakkar A.
        • Hobbs F.D.R.
        • Petrou S.
        • Dale J.
        • Poole C.J.
        • Maraveyas A.
        • Levine M.
        • Young A.M.
        • et al.
        Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D).
        J Clin Oncol. 2018; 36: 2017-2023
        • Agnelli G.
        • Becattini C.
        • Meyer G.
        • Muñoz A.
        • Huisman M.V.
        • Connors J.M.
        • Cohen A.
        • Bauersachs R.
        • Brenner B.
        • Torbicki A.
        • Sueiro M.R.
        • Lambert C.
        • Gussoni G.
        • Campanini M.
        • Fontanella A.
        • Vescovo G.
        • Verso M.
        • Agnelli G.
        • et al.
        • Caravaggio Investigators
        Apixaban for the treatment of venous thromboembolism associated with cancer.
        N Engl J Med. 2020; 382: 1599-1607
      1. Alberto Carmona-Bayonas, et al., A snapshot of cancer-associated thromboembolic disease in 2018-2019: first data from the TESEO prospective registry. Eur J Int Med. doi.org/10.1016/j.ejim.2020.05.031.

        • Angelini D.E.
        • Radivoyevitch T.
        • McCrae K.R.
        • Khorana A.A.
        Bleeding incidence and risk factors among cancer patients treated with anticoagulation.
        Am J Hematol. 2019; 94: 780-785https://doi.org/10.1002/ajh.25494